Hikma Pharmaceuticals

Hikma Pharmaceuticals Available Products-Manufacturing/Production Quality

by

Hikma Pharmaceuticals Available Products-Manufacturing/Production Quality,Hikma Pharmaceuticals is a global company with a local presence in Egypt since 2007. Since then it has grown its  presence in the Egyptian market by using our unique insight to transform cutting edge science into innovative solutions that transform people‘s lives across the country.

At Hikma In Egypt, through our specialised general formulation, cephalosporine and onclogy manufacturing plants, we are producing high quality medicines and making them accessible to the people who need them.

Hikma Pharmaceuticals
Hikma Pharmaceuticals

At Hikma our vision is of a healthier world that enriches all of our communities. Throughout the past 40+ years, we’ve been guided by the simple belief that when world-class medicine is put within people’s reach, it has the ability to transform their lives and their communities.

Contact of Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC
1 New Burlington Place,
London
W1S 2HR
UK

Tel: +44 (0) 20 7399 2760

Fax: +44 (0) 20 7399 2761

Hikma Pharmaceuticals Available Products

Providing over 670 products (as of 31 December 2021) to patients worldwide

We create high-quality medicines, and make them accessible to people who need them.
We have a broad product range and a growing pipeline of new medicines for treating a wide range of diseases. Therapeutic categories include anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management and respiratory.

London, 21 January 2022 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it launched Diazepam Injection, USP, through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 5mg/mL in 2mL dose. This is the second medicine Hikma has launched in prefilled syringe form.

Diazepam, which has been in short supply until recently, is indicated for the management of anxiety, convulsive seizures and alcohol withdrawals.

“We are excited to announce the launch of Diazepam Injection, our second product in prefilled syringe form which may help treat patients faster, more easily and with reduced risk, particularly in time-sensitive situations,” said Riad Mishlawi, President of Hikma Injectables. “We are continuously expanding our portfolio of essential medicines and introducing new dosage forms that enhance patient care.

This launch leverages the investments we have made to expand our Injectables manufacturing capacity and capabilities and we look forward to bringing more medicines in this form to patients and healthcare professionals in the US.”

According to IQVIA, US sales of Diazepam Injection, USP, 5mg/ml in 2mL were approximately $31 million in the 12 months ending November 2021.

Hikma is the second largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 120 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.

Important Safety Information for Diazepam Injection, USP, 5mg/ml in 2mL:

BOXED WARNING

 

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

  • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death (see WARNINGS).
  • Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.
  • Limit dosages and durations to the minimum required.
  • Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS).
  • The use of benzodiazepines, including diazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing diazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS).
  • The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose.
  • Although diazepam is indicated only for intermittent use (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION), if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of diazepam may precipitate acute withdrawal reactions, which can be life-threatening.
  • For patients using diazepam more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam (see WARNINGS).

Leave a Comment